Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron

Scandinavian Journal of Rheumatology, Supplement

Volumn 33, Issue 119, 2004, Pages 59-62

  Stratz, T ^a,b   Muller W ^a  

^a Department of Clinical Research ^*  (Germany)

^b Hochrhein Inst F R   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LAXATIVE; METHOTREXATE; PREDNISONE; SEROTONIN ANTAGONIST; TROPISETRON; INDOLE DERIVATIVE; SEROTONIN 3 RECEPTOR;

ADULT; AGED; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; CONSTIPATION; DISEASE COURSE; FEMALE; FIBROMYALGIA; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; JOINT FUNCTION; LOCOMOTION; PAIN ASSESSMENT; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCORING SYSTEM; SERUM; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE; ARTICLE; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED;

ADULT; FEMALE; HUMANS; INDOLES; MIDDLE AGED; RECEPTORS, SEROTONIN, 5-HT3; SCLERODERMA, SYSTEMIC; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX;

EID: 4444285369     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740410007078     Document Type: Conference Paper

References (4)

1. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 2003;42:191-3.
2. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003;37:1055-62.
3. Stratz T, Muller W. Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias. Fortschritte Medizin 2002;120:17-20.
4. Sule SD, Wigley FM. Treatment of scleroderma: an update. Expert Opin Investig Drugs 2003;12:471-82.